Additional file 1 of MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

Additional file 1: Materials and methods. Table S1 Antibodies for Western blotting, IF, IHC, and IP. Table S2 FACS antibodies. Table S3 shRNA and siRNA sequences. Table S4 Primers for qPCR. Table S5 Clinical arrays. Fig. S1 RFA inhibits tumor progression and induces immune cell infiltration. Fig. S2 RFA treatment increased MELK expression, an independent risk factor in patients with HCC. Fig. S3 MELK knockdown enhances HCC sensitivity to heat treatment and RFA efficacy. Fig. S4 MELK knockdown promotes RFA-induced apoptosis and immunogenic death in hepatoma cells. Fig. S5 MELK knockdown enhances RFA-induced antitumor immune effects in HCC. Fig. S6 The changes in immune cell infiltration in liver tumors after RFA treatment or MELK knockdown. Fig. S7 Tumor cell-intrinsic MELK enhanced the PI3K/Akt/mTOR signal axis and FABP5 interaction. Fig. S8 MELK decreased the Ub level of FABP5 to maintain its stability. Fig. S9 FABP5 is required for the antitumor effect of RFA treatment and MELK knockdown in HCC. Fig. S10 LNPs with RGD-MELK-siRNAs were synthesized. Fig. S11 LNPs-siRNAs targeting tumor cell-intrinsic MELK enhance RFA-induced antitumor immune effects in HCC. Fig. S12 The immune effect and therapeutic toxicity detection.